Medical Oncologist
HER2-targeted treatment
How Long Will You Stay on — Trastuzumab Deruxtecan?
There is no fixed number of cycles with trastuzumab deruxtecan. You continue it for as long as it is keeping your cancer under control and you are tolerating it — and that answer is uncomfortable, but it is the honest one.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- No fixed end date — Unlike some chemotherapy, T-DXd is not given for a set number of cycles and then stopped.
- The signal to stop is clinical — A scan showing the cancer has grown, or a side effect that makes continuing unsafe, is what triggers a change.
- Lung side effects are the key safety concern — Interstitial lung disease (ILD) is the most important reason to pause or permanently stop T-DXd.
- Regular scans confirm it is still working — You do not need to wait for new symptoms — imaging at regular intervals is how your team judges response.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Trastuzumab deruxtecan has no fixed treatment duration. You continue it for as long as it is keeping your cancer under control and the side effects are manageable. NCCN and ASCO guidance describes this as treatment until disease progression or unacceptable toxicity — there is no planned stopping point built into the regimen.
Why is there no fixed number of cycles?
T-DXd is a targeted therapy used in the metastatic setting, where the aim is to keep the cancer controlled for as long as possible. NCCN and ASCO guidance describes the approach as treatment until disease progression or unacceptable toxicity.
This is different from adjuvant chemotherapy, which is given for a fixed course after surgery. In the metastatic setting, stopping and restarting would likely give the cancer an opportunity to grow during the gap.
Your team will assess response at regular intervals with imaging. That scan result — not a calendar date — is what determines whether you continue or whether a change is needed.
What would cause treatment to pause or stop?
Two things trigger a stop: the cancer progressing despite treatment, or a side effect that makes continuing unsafe.
The most important safety reason to stop T-DXd is interstitial lung disease (ILD) — inflammation in the lung tissue. NCCN and ESMO guidelines treat ILD as the most significant risk with T-DXd. New breathlessness, a dry cough, or a change in how easily you breathe must be reported the same day, not at your next scheduled visit.
How your team responds to ILD depends on how severe it is. A mild case may lead to treatment being paused and monitored closely, with a possible restart. A severe case means T-DXd stops permanently. Other side effects — a significant change in heart function, a serious fall in blood counts, or severe nausea — may lead to a temporary hold or a dose reduction rather than permanent stopping.
What to report before your next appointment
- New shortness of breathReport the same day — do not wait for your next scheduled visit.
- A dry cough that appeared after starting treatmentEven if mild, tell your team. ILD can begin with a cough alone.
- Chest tightness or a change in how easily you breatheSame-day call to your oncology team.
- Swelling in your legs or anklesMention it at your next visit, or earlier if it is sudden or new.
- Nausea or vomiting that stops you eating or drinking for more than a dayCall your team — do not wait to see if it passes.
- A scan or test result from another providerBring it at your next appointment, or call the same day if it shows something new.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How will you know if it is still working?
Your team will arrange scans — typically CT or PET-CT — at regular intervals to assess whether the cancer is responding. You do not need to wait for symptoms to change.
A response is described as stable disease, a partial response, or a complete response. In each case the cancer is either not growing or has shrunk, and treatment continues.
If scans show progression — the cancer has grown or spread despite treatment — your oncologist will discuss what comes next. That may be a different drug, a clinical trial, or another approach. Progression on T-DXd is not the end of treatment options.
Words your team may use
- Disease progression
- The cancer has grown or spread while you were on T-DXd. This is the main clinical signal to stop and consider an alternative.
- Stable disease
- The cancer has neither shrunk nor grown significantly. This counts as a response — treatment continues.
- Partial response
- The cancer has measurably shrunk. Treatment continues.
- ILD (interstitial lung disease)
- Inflammation in the lung tissue. The most important safety reason to pause or permanently stop T-DXd.
- Dose reduction
- A lower amount of T-DXd given when a side effect is significant but manageable. The drug continues at the adjusted amount rather than stopping.
- Treatment hold
- A planned pause in T-DXd while a side effect resolves. Treatment may restart at the same or a lower dose if the side effect settles fully.
Did you know?
The approach of continuing treatment without a planned end date — treat until progression — was not how most cancer therapy worked even two decades ago, when fixed courses were the norm.
For targeted therapies that act on specific tumour markers the way T-DXd targets HER2, ASCO and ESMO educational guidance notes that continuous treatment has produced better outcomes than stopping after a fixed number of cycles.
Source: ASCO and ESMO guidance on antibody-drug conjugate and targeted therapy principles
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is there a maximum number of T-DXd cycles I can have?
No maximum number of cycles is set by NCCN, ASCO or ESMO guidelines for T-DXd in the metastatic setting. The number you have depends on how well the cancer is responding and how well you are tolerating treatment, not on an arbitrary ceiling. Some people continue for well over a year; others reach a stopping signal sooner. The signal is always clinical — a scan result or a side effect — never a cycle count.
What happens if the cancer stops responding to T-DXd?
Your oncologist will discuss alternatives that depend on your cancer type, what treatments you have already had, and what is available at your centre. For HER2-positive breast cancer, for example, other HER2-targeted options exist. Stopping T-DXd because it is no longer working is not the end of treatment — it is a pivot to a different approach. Ask your oncologist specifically what the next line would be in your situation.
If I develop ILD, does that always mean treatment stops permanently?
Not always — it depends on how severe the ILD is. Mild ILD may lead to a pause and close monitoring, with a possible restart if it resolves fully and your team judges a restart safe. Severe ILD requires permanent discontinuation. NCCN and ESMO guidelines are clear that any new breathlessness or cough on T-DXd must be assessed urgently. How quickly you report it makes a significant difference to the outcome.
Can I take a break from T-DXd and restart later?
An unplanned break — stopping for a reason other than a medical one — is not generally recommended. In the metastatic setting, T-DXd is intended as continuous treatment, and pausing without a clinical reason may allow the cancer to grow during the gap. If you need a break for personal, practical or quality-of-life reasons, discuss it with your oncologist first so the risks can be weighed against your specific situation.
How will my team know T-DXd is working without waiting for new symptoms?
Imaging — typically a CT scan or PET-CT — is done at regular intervals regardless of how you feel. Cancer in early response often produces no new symptoms, which is exactly why scan-based assessment exists. You may feel the same, better, or no different at a time when scans are already showing a response. How you feel is important information, but it is not the measure of whether treatment is working.
What if I feel fine but scans show the cancer has progressed?
Feeling well does not always mean treatment is still working, because cancer can grow without producing symptoms you would notice. This is one of the hardest messages to receive. If that happens, your oncologist will explain clearly what the scans show and what the next step is. It does not mean your overall options have run out — it means T-DXd is no longer the right tool and another approach needs to be considered.